Expression and Association of CD44v6 with Prognosis in T2-3N0M0 Esophageal Squamous Cell Carcinoma

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2014 Mar 8

PMID 24605222

Citations 5

Authors

Han Yang

Junling Liu

Hui Yu

Peng Sun

Yi Hu

Jiudi Zhong

Zhihua Zhu

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the expression of CD44v6 in stage T2-3N0M0 esophageal squamous cell carcinoma (ESCC) and its prognostic significance.

Methods: The expression of CD44v6 in a series of 227 ESCC specimens was evaluated by immunohistochemistry (IHC). A reproducible semiquantitative method which took both staining percentage and intensity into account was applied for IHC scoring, and receiver operating characteristic (ROC) curve analysis was utilized to select the cut-off score for high or low IHC reactivity. Then, the correlations of CD44v6 expression with clinicopathological features of patients and its prognostic relevance were determined.

Results: In the present study, the proportion of low CD44v6 expression was found significantly lower in Grade 3 of ESCC, than that of Grade 1 and Grade 2 of ESCC. There are no significant correlations between CD44v6 expression and other clinicopathological parameters including gender, age, tumor size, tumor location, depth of invasion and pathological stage. The Kaplan-Meier survival curves showed that up-regulated expression of CD44v6 indicated a poorer post-operative survival for ESCC patients of stage T2-3N0M0 (P=0.009), especially for those with T2 lesions (P=0.044) or with stage IIB diseases (P=0.005). Multivariate analysis also confirmed that CD44v6 expression [relative risk, 1.639; 95% confidence interval (CI): 1.142-2.354, P=0.007] and depth of invasion (relative risk, 1.487; 95% CI: 1.063-2.080, P=0.020) were independent prognostic factors.

Conclusions: Elevated CD44v6 expression may be an adverse prognostic indicator for patients with stage T2-3N0M0 ESCC, especially for those with T2 lesions or stage IIB diseases.

Citing Articles

Critical role of VHL/BICD2/STAT1 axis in crystal-associated kidney disease.

Hao W, Zhang H, Hong P, Zhang X, Zhao X, Ma L Cell Death Dis. 2023; 14(10):680.

PMID: 37833251 PMC: 10575931. DOI: 10.1038/s41419-023-06185-1.

Autophagy supports generation of cells with high CD44 expression via modulation of oxidative stress and Parkin-mediated mitochondrial clearance.

Whelan K, Chandramouleeswaran P, Tanaka K, Natsuizaka M, Guha M, Srinivasan S Oncogene. 2017; 36(34):4843-4858.

PMID: 28414310 PMC: 5570661. DOI: 10.1038/onc.2017.102.

Prognostic significance of CD44V6 expression in osteosarcoma: a meta-analysis.

Zhang Y, Ding C, Wang J, Sun G, Cao Y, Xu L J Orthop Surg Res. 2015; 10:187.

PMID: 26697855 PMC: 4690422. DOI: 10.1186/s13018-015-0328-z.

Meta-Analysis of Prognostic and Clinical Significance of CD44v6 in Esophageal Cancer.

Hu B, Luo W, Hu R, Zhou Y, Qin S, Jiang H Medicine (Baltimore). 2015; 94(31):e1238.

PMID: 26252284 PMC: 4616606. DOI: 10.1097/MD.0000000000001238.

Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Niu Z, Niu X, Wang M World J Hepatol. 2015; 7(1):7-27.

PMID: 25624992 PMC: 4295195. DOI: 10.4254/wjh.v7.i1.7.

References

Ponta H, Wainwright D, Herrlich P . The CD44 protein family. Int J Biochem Cell Biol. 1998; 30(3):299-305. DOI: 10.1016/s1357-2725(97)00152-0. View

Zhou D, Liu Y, Xue Y . Expression of CD44v6 and Its Association with Prognosis in Epithelial Ovarian Carcinomas. Patholog Res Int. 2012; 2012:908206. PMC: 3317067. DOI: 10.1155/2012/908206. View

Koyama S, Maruyama T, Adachi S . Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: a two-color flow-cytometric analysis. J Cancer Res Clin Oncol. 1999; 125(1):47-54. DOI: 10.1007/s004320050241. View

Fonseca I, Pereira T, Rosa-Santos J, Soares J . Expression of CD44 isoforms in squamous cell carcinoma of the border of the tongue: A correlation with histological grade, pattern of stromal invasion, and cell differentiation. J Surg Oncol. 2001; 76(2):115-20. DOI: 10.1002/1096-9098(200102)76:2<115::aid-jso1021>3.0.co;2-9. View

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T . Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4):220-41. DOI: 10.3322/caac.21149. View

Yu Y, Wang B, Zhang K, Lei Z, Guo Y, Xiao H . High expression of lysine-specific demethylase 1 correlates with poor prognosis of patients with esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2013; 437(2):192-8. DOI: 10.1016/j.bbrc.2013.05.123. View

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

Situ D, Hu Y, Zhu Z, Wang J, Long H, Rong T . Prognostic relevance of β-catenin expression in T2-3N0M0 esophageal squamous cell carcinoma. World J Gastroenterol. 2010; 16(41):5195-202. PMC: 2975090. DOI: 10.3748/wjg.v16.i41.5195. View

Rodrigo J, Dominguez F, Alvarez C, Gonzalez M, Herrero A, Suarez C . Clinicopathologic significance of expression of CD44s and CD44v6 isoforms in squamous cell carcinoma of the supraglottic larynx. Am J Clin Pathol. 2002; 118(1):67-72. DOI: 10.1309/F50H-6MLG-R7LM-2XFT. View

10.

Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N . CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One. 2011; 6(9):e24217. PMC: 3167830. DOI: 10.1371/journal.pone.0024217. View

11.

Lambert R . Endoscopy in screening for digestive cancer. World J Gastrointest Endosc. 2013; 4(12):518-25. PMC: 3536848. DOI: 10.4253/wjge.v4.i12.518. View

12.

Spira A, Ettinger D . Multidisciplinary management of lung cancer. N Engl J Med. 2004; 350(4):379-92. DOI: 10.1056/NEJMra035536. View

13.

Ekman S, Dreilich M, Lennartsson J, Wallner B, Brattstrom D, Sundbom M . Esophageal cancer: current and emerging therapy modalities. Expert Rev Anticancer Ther. 2008; 8(9):1433-48. DOI: 10.1586/14737140.8.9.1433. View

14.

Parkin D, Bray F, Devesa S . Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001; 37 Suppl 8:S4-66. DOI: 10.1016/s0959-8049(01)00267-2. View

15.

Afify A, Purnell P, Nguyen L . Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol. 2009; 86(2):95-100. DOI: 10.1016/j.yexmp.2008.12.003. View

16.

Shen W, Ji Y, Liu P, Xiang B, Chen G, Huang B . Correlation of E-cadherin and CD44v6 expression with clinical pathology in esophageal carcinoma. Mol Med Rep. 2011; 5(3):817-21. DOI: 10.3892/mmr.2011.693. View

17.

Martin T, Harrison G, Mansel R, Jiang W . The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol. 2003; 46(2):165-86. DOI: 10.1016/s1040-8428(02)00172-5. View

18.

Situ D, Long H, Lin P, Zhu Z, Wang J, Zhang X . Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma. J Cancer Res Clin Oncol. 2010; 136(8):1213-9. DOI: 10.1007/s00432-010-0771-5. View

19.

Morris S, OHanlon D, McLaughlin R, McHale T, Connolly G, Given H . The prognostic significance of CD44s and CD44v6 expression in stage two breast carcinoma: an immunohistochemical study. Eur J Surg Oncol. 2001; 27(6):527-31. DOI: 10.1053/ejso.2001.1167. View

20.

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View